Telavancin

WikiDoc Resources for Telavancin
Articles
Most recent articles on Telavancin Most cited articles on Telavancin Review articles on Telavancin Articles on Telavancin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Telavancin Images of Telavancin Photos of Telavancin Podcasts & MP3s on Telavancin Videos on Telavancin
Evidence Based Medicine
Cochrane Collaboration on Telavancin Bandolier on Telavancin TRIP on Telavancin
Clinical Trials
Ongoing Trials on Telavancin at Clinical Trials.gov Trial results on Telavancin Clinical Trials on Telavancin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Telavancin NICE Guidance on Telavancin NHS PRODIGY Guidance FDA on Telavancin CDC on Telavancin
Books
Books on Telavancin
News
Telavancin in the news Be alerted to news on Telavancin News trends on Telavancin
Commentary
Blogs on Telavancin
Definitions
Definitions of Telavancin
Patient Resources / Community
Patient resources on Telavancin Discussion groups on Telavancin Patient Handouts on Telavancin Directions to Hospitals Treating Telavancin Risk calculators and risk factors for Telavancin
Healthcare Provider Resources
Symptoms of Telavancin Causes & Risk Factors for Telavancin Diagnostic studies for Telavancin Treatment of Telavancin
Continuing Medical Education (CME)
CME Programs on Telavancin
International
Telavancin en Espanol Telavancin en Francais
Business
Telavancin in the Marketplace Patents on Telavancin
Experimental / Informatics
List of terms related to Telavancin

Telavancin is a bactericidal lipoglycopeptide under trial for use in MRSA or other Gram-positive infections.

On October 19, 2007, the US Food and Drug Administration issued an approvable letter for telavancin. Its developer, Theravance, Inc. submitted a complete response to the letter, and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of July 21, 2008.

External links

• Theravance, Inc.